Renal denervation therapy for hypertension: Pathways for moving development forward

Journal of the American Society of Hypertension

Volumn 9, Issue 5, 2015, Pages 341-350

  White, William B ^a   Galis, Zorina S ^b   Henegar, Jeffrey ^c   Kandzari, David E ^d   Victor, Ronald ^e   Sica, Domenic ^f   Townsend, Raymond R ^g   Turner, J Rick ^h   Virmani, Renu ⁱ   Mauri, Laura ^j  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d PIEDMONT HEART INSTITUTE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h IQVIA   (United States)

ⁱ CVPATH INSTITUTE   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

American Society of Hypertension; clinical trials; device therapy for hypertension; renal denervation

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; DEVICE THERAPY; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY PERFUSION; KIDNEY TUBULE ABSORPTION; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESISTANT HYPERTENSION; STUDY DESIGN; UROLOGICAL EQUIPMENT; ANIMAL; CLINICAL TRIAL (TOPIC); DENERVATION; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DENERVATION; HUMANS; HYPERTENSION; KIDNEY;

EID: 84929403383     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2015.02.012     Document Type: Article

References (37)

1. American Society of Hypertension web page. Available at: www.ash-us.org. Accessed on January 7, 2014.
2. P.A. Sobotka, F. Mahfoud, M.P. Schlaich, U.C. Hoppe, M. Böhm, and H. Krum Sympatho-renal axis in chronic disease Clin Res Cardiol 100 2011 1049 1057
3. D.S. Atherton, N.L. Deep, and F.O. Mendelsohn Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study Clin Anat 25 2012 628 633
4. K. Sakakura, E. Ladich, Q. Cheng, F. Otsuka, K. Yahagi, and D.R. Fowler Anatomic assessment of sympathetic peri-arterial renal nerves in man J Am Coll Cardiol 64 2014 635 643
5. H.C. Patel, P.S. Dhillon, F. Mahfoud, A.C. Lindsay, C. Hayward, and S. Ernst The biophysics of renal sympathetic denervation using radiofrequency energy Clin Res Cardiol 103 2014 337 344
6. M. Böhm, D. Linz, C. Ukena, M. Esler, and F. Mahfoud Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? Circ Res 115 2014 400 409
7. W.B. White, J.R. Turner, D.A. Sica, J.D. Bisognano, D.A. Calhoun, and R.R. Townsend Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, MD, USA, October 10th, 2013 J Am Soc Hypertens 8 2014 743 757
8. H. Krum, M. Schlaich, R. Whitbourn, P.A. Sobotka, J. Sadowski, and K. Bartus Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 2009 1275 1281
9. H. Krum, M.P. Schlaich, P. Sobotka, M. Bohm, F. Mahfoud, and K. Rocha-Singh Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study Lancet 383 2014 622 629
10. Symplicity HTN-2 Investigators M.D. Esler, H. Krum, P.A. Sobotka, M.P. Schlaich, R.E. Schmieder, and M. Böhm Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet 376 2010 1903 1909
11. F. Mahfoud, C. Ukena, R.E. Schmieder, B. Cremers, L.C. Rump, and O. Vonend Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension Circulation 128 2013 132 140
12. J. Rosa, P. Widimsky, P. Tousek, O. Petrak, K. Curila, and P. Waldauf Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 Study Hypertension 65 2015 407 413
13. D.L. Bhatt, D.E. Kandzari, W.W. O'Neill, R. D'Agostino, J.M. Flack, B.T. Katzen SYMPLICITY HTN-3 Investigators A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 2014 1393 1401
14. G.L. Bakris, R.R. Townsend, M. Liu, S.A. Cohen, R. D'Agostino, J.M. Flack SYMPLICITY HTN-3 Investigators Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3 J Am Coll Cardiol 64 2014 1071 1078
15. S. Nathan, and G.L. Bakris The future of renal denervation in resistant hypertension Curr Hypertens Rep 16 2014 494 499
16. D. Kandzari, D.L. Bhatt, S. Brar, C.M. Devireddy, M. Esler, and M. Fahy Predictors of blood pressure response in the SYMPLICITY HTN-3 trial Eur Heart J 36 2015 219 227
17. G.F. DiBona, and M. Esler Translational medicine: the antihypertensive effect of renal denervation Am J Physiol Regul Integr Comp Physiol 298 2010 R245 R253
18. R.J. Roman, and A.W. Cowley Jr. Characterization of a new model for the study of pressure-natriuresis in the rat Am J Physiol 248 2 Pt 2 1985 F190 F198
19. Z.S. Galis, T. Thrasher, D.M. Reid, D.V. Stanley, and Y.S. Oh Investing in high blood pressure research: a National Institutes of Health perspective Hypertension 61 2013 757 761
20. J.R. Henegar, Y. Zhang, R. De Rama, C. Hata, M.E. Hall, and J.E. Hall Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs Am J Hypertens 27 2014 1285 1292
21. J.E. Hall, M.W. Brands, and J.R. Henegar Mechanisms of hypertension and kidney disease in obesity Ann N Y Acad Sci 892 1999 91 107
22. Q. Wang, R. Guo, S. Rong, G. Yang, Q. Zhu, and Y. Jiang Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model J Am Coll Cardiol 61 2013 2185 2192
23. S. Hiremath, M. Froeschl, and M. Ruzicka Catheter-based renal sympathetic denervation: limitations to and gaps in the evidence Curr Opin Cardiol 29 2014 336 343
24. D. Linz, K. Wirth, C. Ukena, F. Mahfoud, J. Pöss, and B. Linz Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs Heart Rhythm 10 2013 1525 1530
25. D. Linz, M. Hohl, A. Nickel, F. Mahfoud, M. Wagner, and S. Ewen Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea Hypertension 62 2013 767 774
26. M.P. Schlaich, D. Hering, P. Sobotka, H. Krum, G.W. Lambert, and E. Lambert Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension Front Physiol 3 2012 10
27. C. Tsioufis, V. Papademetriou, K. Dimitriadis, D. Tsiachris, C. Thomopoulos, and E. Park Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine Int J Cardiol 168 2013 987 992
28. K. Sakakura, E. Ladich, E.R. Edelman, P. Markham, J.R. Stanley, and J. Keating Methodological standardization for the pre-clinical evaluation of renal sympathetic denervation JACC Cardiovasc Interv 7 2014 1184 1193
29. W.B. White, and S.J. Walsh Ambulatory monitoring of the blood pressure in multicenter clinical trials Blood Press Monit 1 1996 227 229
30. W.B. White, M.A. Weber, D. Sica, G.L. Bakris, A. Perez, and C. Cao Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension Hypertension 57 2011 413 420
31. A. DeFelice, J. Willard, J. Lawrence, J. Hung, M.A. Gordon, and A. Karkowsky The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis J Hum Hypertens 22 2008 659 668
32. M.B. Leon, R. Kornowski, W.E. Downey, G. Weisz, D.S. Baim, and R.O. Bonow A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease J Am Coll Cardiol 46 2005 1812 1819
33. W.B. White, V. Hanes, V. Chauhan, and B. Pitt Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension Hypertension 48 2006 246 253
34. G.L. Bakris, L.H. Lindholm, H.R. Black, H. Krum, S. Linas, and J.V. Linseman Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial Hypertension 56 2010 824 830
35. W.B. White Utilizing ambulatory blood pressure recordings to evaluate antihypertensive drug therapy Am J Cardiol 69 1992 8E 12E
36. V. Papademetriou, C. Tsioufis, and M. Doumas Renal denervation and SYMPLICITY HTN-3: "Dubium sapientaie initium" (doubt is the beginning of wisdom) Circ Res 115 2014 211 214
37. M. Esler Illusions of truths in the SYMPLICITY HTN-3 trial: generic design strengths but neuroscience failings J Am Soc Hypertens 8 2014 593 598